2-Amino-3-[3-(2-chlorophenyl)-5-(phosphonomethyl)phenyl]propanoic acid

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 2-Amino-3-[3-(2-chlorophenyl)-5-(phosphonomethyl)phenyl]propanoic acid
• 化学式: C₁₆H₁₇ClNO₅P
• 分子量: 369.73
• InChiKey: VBRJFXSFCYEZMQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.2
• 重原子数：
  24
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  121
• 氢给体数：
  4
• 氢受体数：
  6

文献信息

• [EN] AMINOMETHYL- AND METHYLOXY-LINKED TRICYCLIC COMPOUNDS AS INHIBITORS OF PROTEIN AGGREGATION<br/>[FR] COMPOSÉS TRICYCLIQUES À LIAISON ANIMOMÉTHYLE ET MÉTHYLOXY UTILISÉS EN TANT QU'INHIBITEURS DE L'AGRÉGATION DE PROTÉINES
  申请人：NEUROPORE THERAPIES INC

  公开号：WO2016040780A1

  公开（公告）日：2016-03-17

  The present invention relates to certain aminomethyl- and methyloxy-linked tricyclic compounds, pharmaceutical compositions containing them, and methods of using them, including methods for preventing, reversing, slowing, or inhibiting protein aggregation, and methods of treating diseases that are associated with protein aggregation, including neurodegenerative diseases such as Parkinson's disease, Alzheimer's disease, Lewy body disease, Parkinson's disease dementia, fronto-temporal dementia, Huntington's Disease, amyotrophic lateral sclerosis, and multiple system atrophy.

  本发明涉及某些氨甲基和甲氧基连接的三环化合物、含有它们的药物组成物以及使用它们的方法，包括预防、逆转、减缓或抑制蛋白质聚集的方法，以及治疗与蛋白质聚集有关的疾病的方法，包括神经退行性疾病，如帕金森病、阿尔茨海默病、路易体病、帕金森病性痴呆、额颞叶痴呆、亨廷顿病、肌萎缩侧索硬化和多系统萎缩等。
• 1H-QUINAZOLINE-2,4-DIONES
  申请人：NOVARTIS AG

  公开号：US20130296332A1

  公开（公告）日：2013-11-07

  The present invention relates to 1H-Quinazoline-2,4-diones of formula (I) wherein R 1 and R 2 are as defined in the specification, their preparation, their use as pharmaceuticals, and pharmaceutical compositions containing them. Further, intermediates for the manufacture of compounds of formula (I) are and combinations comprising compounds of formula (I) are disclosed.

  本发明涉及公式(I)的1H-喹唑啉-2,4-二酮，其中R1和R2如规范所定义，它们的制备，它们作为药物的用途，以及含有它们的药物组合物。此外，还公开了制造公式(I)化合物的中间体和包含公式(I)化合物的组合物。
• 1H-Quinazoline-2,4-Diones
  申请人：Allgeier Hans

  公开号：US20080153836A1

  公开（公告）日：2008-06-26

  The present invention relates to 1H-Quinazoline-2,4-diones of formula (I) wherein R 1 and R 2 are as defined in the specification, their preparation, their use as pharmaceuticals, and pharmaceutical compositions containing them. Further, intermediates for the manufacture of compounds of formula (I) are and combinations comprising compounds of formula (I) are disclosed.

  本发明涉及公式（I）的1H-喹唑啉-2,4-二酮，其中R1和R2如规范中所定义，它们的制备，它们作为药物的用途以及含有它们的药物组合物。此外，还揭示了制造公式（I）化合物的中间体和包含公式（I）化合物的组合物。
• Quinazoline Derivatives
  申请人：Allgeier Hans

  公开号：US20070208018A1

  公开（公告）日：2007-09-06

  The present invention relates to 1H-Quinazoline-2,4-dione derivatives of formula(I) wherein the substituents are defined as in the specification, their preparation, their use as pharmaceuticals, and pharmaceutical compositions containing them.

  本发明涉及式(I)的1H-喹唑啉-2,4-二酮衍生物，其中取代基的定义如规范中所述，它们的制备方法，它们作为药物的用途，以及含有它们的药物组合物。
• TETRAHYDROTRIAZOLOPYRIDINE COMPOUNDS AS SELECTIVE MGLU5 RECEPTOR POTENTIATORS USEFUL FOR THE TREATMENT OF SCHIZOPHRENIA
  申请人：Prieto Lourdes

  公开号：US20120252838A1

  公开（公告）日：2012-10-04

  The present invention provides certain tetrahydrotriazolopyridine derivatives, pharmaceutical compositions thereof, methods of using the same and processes for preparing the same. Formula (I) wherein R 1 is hydrogen, fluoro, chloro, or methyl; and R 2 is C4-CS branched alkyl.

  本发明提供了某些四氢三唑吡啶衍生物，其药物组成物，使用方法和制备方法。其中公式（I）中，R1是氢、氟、氯或甲基；R2是C4-CS支链烷基。